NO20092473L - Kombinasjon - Google Patents

Kombinasjon

Info

Publication number: NO20092473L
Authority: NO; Norway
Prior art keywords: combination; aml; mds; hdai; contributory
Prior art date: 2006-12-04

Application number

NO20092473A

Other languages

English (en)

Norwegian (no)

Inventor

Peter Wisdom Atadja

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-04

Filing date

2009-06-30

Publication date

2009-09-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39272127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20092473(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-06-30 Application filed by Novartis Ag filed Critical Novartis Ag

2009-09-01 Publication of NO20092473L publication Critical patent/NO20092473L/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Oncology (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20092473A 2006-12-04 2009-06-30 Kombinasjon NO20092473L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US86838806P	2006-12-04	2006-12-04
PCT/US2007/024712 WO2008070011A2 (fr)	2006-12-04	2007-11-30	Combinaison

Publications (1)

Publication Number	Publication Date
NO20092473L true NO20092473L (no)	2009-09-01

Family

ID=39272127

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20092473A NO20092473L (no)	2006-12-04	2009-06-30	Kombinasjon

Country Status (25)

Country	Link
US (1)	US8093220B2 (fr)
EP (1)	EP2099451B1 (fr)
JP (3)	JP5784274B2 (fr)
KR (1)	KR101475538B1 (fr)
CN (1)	CN101553223A (fr)
AR (1)	AR064072A1 (fr)
AU (1)	AU2007328281B2 (fr)
BR (1)	BRPI0719746A2 (fr)
CA (1)	CA2670741C (fr)
CL (1)	CL2007003467A1 (fr)
EC (1)	ECSP099483A (fr)
ES (1)	ES2569477T3 (fr)
GT (1)	GT200900148A (fr)
IL (1)	IL198638A (fr)
MA (1)	MA30982B1 (fr)
MX (1)	MX2009005946A (fr)
MY (1)	MY148893A (fr)
NO (1)	NO20092473L (fr)
PE (1)	PE20081303A1 (fr)
PL (1)	PL2099451T3 (fr)
RU (1)	RU2469717C2 (fr)
TN (1)	TN2009000213A1 (fr)
TW (1)	TW200831075A (fr)
WO (1)	WO2008070011A2 (fr)
ZA (1)	ZA200903041B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2260020B1 (fr)	2008-03-26	2014-07-23	Novartis AG	Inhibiteurs de désacétylases b à base d'hydroxamate
AU2009270886A1 (en) *	2008-07-18	2010-01-21	Novartis Ag	Use of HDAC inhibitors for the treatment of Hodgkin's disease
WO2010009285A1 (fr) *	2008-07-18	2010-01-21	Novartis Ag	Utilisation d'inhibiteurs de hdac pour le traitement d'une leucémie myéloïde aiguë et/ou d'un syndrome myélodysplasique
US20110053925A1 (en) *	2009-08-28	2011-03-03	Novartis Ag	Hydroxamate-Based Inhibitors of Deacetylases
NZ707377A (en) *	2010-06-07	2015-09-25	Abraxis Bioscience Llc	Combination therapy methods for treating proliferative diseases
RU2013114246A (ru) *	2010-09-01	2014-10-20	Новартис Аг	Комбинация hdac ингибиторов с лекарственными средствами против тромбоцитопении
WO2014164708A1 (fr)	2013-03-12	2014-10-09	Quanticel Pharmaceuticals, Inc.	Inhibiteurs d'histone déméthylase
US9757385B2 (en)	2013-11-27	2017-09-12	Merck Sharp & Dohme Corp.	Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds
JP6723663B2 (ja)	2014-09-17	2020-07-15	セルジーンクオンティセルリサーチ，インク．	ヒストンデメチラーゼ阻害剤
KR20170124602A (ko)	2015-03-13	2017-11-10	포르마 세라퓨틱스 인크.	Hdac8 억제제로서의 알파-신나미드 화합물 및 조성물
US10537585B2 (en)	2017-12-18	2020-01-21	Dexcel Pharma Technologies Ltd.	Compositions comprising dexamethasone

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20020354A1 (es) *	2000-09-01	2002-06-12	Novartis Ag	Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US6905669B2 (en) *	2001-04-24	2005-06-14	Supergen, Inc.	Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
CN1791396A (zh) *	2003-05-21	2006-06-21	诺瓦提斯公司	组蛋白脱乙酰基酶抑制剂与化疗剂的组合

2007
- 2007-11-30 ES ES07862420.2T patent/ES2569477T3/es active Active
- 2007-11-30 AR ARP070105351A patent/AR064072A1/es unknown
- 2007-11-30 BR BRPI0719746-2A2A patent/BRPI0719746A2/pt not_active IP Right Cessation
- 2007-11-30 CN CNA2007800429689A patent/CN101553223A/zh active Pending
- 2007-11-30 US US12/516,656 patent/US8093220B2/en not_active Expired - Fee Related
- 2007-11-30 WO PCT/US2007/024712 patent/WO2008070011A2/fr not_active Ceased
- 2007-11-30 PE PE2007001696A patent/PE20081303A1/es not_active Application Discontinuation
- 2007-11-30 CA CA2670741A patent/CA2670741C/fr not_active Expired - Fee Related
- 2007-11-30 MX MX2009005946A patent/MX2009005946A/es active IP Right Grant
- 2007-11-30 RU RU2009125439/15A patent/RU2469717C2/ru not_active IP Right Cessation
- 2007-11-30 MY MYPI20091975A patent/MY148893A/en unknown
- 2007-11-30 JP JP2009540242A patent/JP5784274B2/ja not_active Expired - Fee Related
- 2007-11-30 EP EP07862420.2A patent/EP2099451B1/fr active Active
- 2007-11-30 AU AU2007328281A patent/AU2007328281B2/en not_active Ceased
- 2007-11-30 KR KR1020097013917A patent/KR101475538B1/ko not_active Expired - Fee Related
- 2007-11-30 PL PL07862420T patent/PL2099451T3/pl unknown
- 2007-12-03 TW TW096145961A patent/TW200831075A/zh unknown
- 2007-12-03 CL CL200703467A patent/CL2007003467A1/es unknown
2009
- 2009-05-04 ZA ZA200903041A patent/ZA200903041B/xx unknown
- 2009-05-07 IL IL198638A patent/IL198638A/en active IP Right Grant
- 2009-05-29 TN TNP2009000213A patent/TN2009000213A1/fr unknown
- 2009-06-03 GT GT200900148A patent/GT200900148A/es unknown
- 2009-06-10 MA MA31973A patent/MA30982B1/fr unknown
- 2009-06-30 NO NO20092473A patent/NO20092473L/no not_active Application Discontinuation
- 2009-07-03 EC EC2009009483A patent/ECSP099483A/es unknown
2013
- 2013-12-26 JP JP2013269307A patent/JP2014097992A/ja active Pending
2015
- 2015-07-21 JP JP2015144342A patent/JP2016006070A/ja active Pending

Also Published As

Publication number	Publication date
AU2007328281A1 (en)	2008-06-12
BRPI0719746A2 (pt)	2013-12-10
GT200900148A (es)	2011-08-02
KR101475538B1 (ko)	2014-12-22
TN2009000213A1 (en)	2010-10-18
ES2569477T3 (es)	2016-05-11
MY148893A (en)	2013-06-14
RU2009125439A (ru)	2011-01-20
CA2670741A1 (fr)	2008-06-12
RU2469717C2 (ru)	2012-12-20
HK1132462A1 (zh)	2010-02-26
EP2099451A2 (fr)	2009-09-16
MA30982B1 (fr)	2009-12-01
EP2099451B1 (fr)	2016-02-10
PL2099451T3 (pl)	2016-07-29
MX2009005946A (es)	2009-06-17
CL2007003467A1 (es)	2008-07-11
KR20090087115A (ko)	2009-08-14
WO2008070011A3 (fr)	2008-07-24
WO2008070011A2 (fr)	2008-06-12
IL198638A (en)	2015-06-30
CN101553223A (zh)	2009-10-07
CA2670741C (fr)	2016-04-12
US20100069318A1 (en)	2010-03-18
AR064072A1 (es)	2009-03-11
JP5784274B2 (ja)	2015-09-24
JP2014097992A (ja)	2014-05-29
JP2016006070A (ja)	2016-01-14
IL198638A0 (en)	2010-02-17
TW200831075A (en)	2008-08-01
US8093220B2 (en)	2012-01-10
PE20081303A1 (es)	2008-10-28
AU2007328281B2 (en)	2011-03-31
ZA200903041B (en)	2010-03-31
JP2010511702A (ja)	2010-04-15
ECSP099483A (es)	2009-08-28

Similar Documents

Publication	Publication Date	Title
NO20092473L (no)	2009-09-01	Kombinasjon
NO20074999L (no)	2007-12-03	Metode og preparat for behandling av perifere vaskulaere sykdommer
UY32177A (es)	2010-05-31	Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
EA201300121A1 (ru)	2014-12-30	Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
EA200870185A1 (ru)	2008-12-30	Комбинации ингибиторов ang2 и vegf
EA200901308A1 (ru)	2010-04-30	Ингибиторы белка, активирующего 5-липоксигеназу (flap)
MY164581A (en)	2018-01-15	Purin derivatives for use in the treatment of fab-related diseases
BRPI0622054B8 (pt)	2021-05-25	composto e composição farmacêutica
WO2007058990A3 (fr)	2007-12-06	Therapie a base d’inhibiteurs de cytokine
EA201100266A1 (ru)	2011-10-31	Диокса-бицикло[3.2.1]октан-2,3,4-триольные производные
MY198422A (en)	2023-08-29	Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
BR112014011645A2 (pt)	2017-05-02	combinação de um inibidor da fosfoinositida 3-quinase e um modulador da quinase janus 2-transdutor de sinal e ativador da via de transcrição 5
BR112015011497A2 (pt)	2017-07-11	composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença
EA201290131A1 (ru)	2012-08-30	Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
UA96441C2 (ru)	2011-11-10	Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением
MX2011007397A (es)	2011-08-03	Inhibidores de dpp-iv para el tratamiento de la diabetes en pacientes pediatricos.
MY151159A (en)	2014-04-30	5-lipoxygenase-activating protien (flap) inhibitors
MX2010002410A (es)	2010-03-26	Metodo para proveer los beneficios de energia, alivio del estres y mejora del estado de animo, que comprende administrar una composicion que comprende colecalciferol y un extracto de te.
EA200801164A2 (ru)	2008-10-30	Ингибиторы протеина, активирующего 5-липоксигеназу (flap)
NO20074318L (no)	2007-10-24	Anvendelse av en fettsyresammensetning som inneholder DHA for fremstilling av et medisinsk produkt eller et naeringsmiddel for behandling av amyloidoserelaterte sykdommer
UA101903C2 (ru)	2013-05-13	Лекарственное средство на основе дииндолилметана для лечения гиперпластических и воспалительных заболеваний
CO6640335A2 (es)	2013-03-22	Tratamiento terapéutico para síndrome metabólico, diabetes de tipo 2, obesidad o prediabetes
MX2010006206A (es)	2011-03-04	Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
CY1116216T1 (el)	2017-02-08	Μεθοδος θεραπειας ασθενειας αποθηκευσης γλυκογονου
EA200970345A1 (ru)	2009-10-30	Лечение гипербилирубинемии новорожденных с использованием низких дозировок станнсопорфина

Legal Events

Date	Code	Title	Description
2018-07-09	FC2A	Withdrawal, rejection or dismissal of laid open patent application